Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Groen K, Schjesvold FH, van der Holt B, Levin MD, Seefat MR, Hansson M, Leys MBL, Regelink JC, Waage A, Szatkowski D, Axelsson P, Hieu Do T, Svirskaite A, van der Spek E, Haukas E, Knut-Bojanowska D, Ypma PF, Blimark CH, Mellqvist UH, van de Donk NWCJ, Sonneveld P, Klostergaard A, Vangsted AJ, Abildgaard N, Zweegman S.

Open source

DOI: 10.1097/hs9.0000000000000940
Published: 2023-08-30
Container: Hemasphere
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hs9.0000000000000940,
  title = {Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.},
  author = {Groen K and  Schjesvold FH and  van der Holt B and  Levin MD and  Seefat MR and  Hansson M and  Leys MBL and  Regelink JC and  Waage A and  Szatkowski D and  Axelsson P and  Hieu Do T and  Svirskaite A and  van der Spek E and  Haukas E and  Knut-Bojanowska D and  Ypma PF and  Blimark CH and  Mellqvist UH and  van de Donk NWCJ and  Sonneveld P and  Klostergaard A and  Vangsted AJ and  Abildgaard N and  Zweegman S.},
  year = {2023},
  journal = {Hemasphere},
  doi = {10.1097/hs9.0000000000000940},
  url = {https://doi.org/10.1097/hs9.0000000000000940}
}

RIS

TY  - JOUR
TI  - Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.
AU  - Groen K
AU  -  Schjesvold FH
AU  -  van der Holt B
AU  -  Levin MD
AU  -  Seefat MR
AU  -  Hansson M
AU  -  Leys MBL
AU  -  Regelink JC
AU  -  Waage A
AU  -  Szatkowski D
AU  -  Axelsson P
AU  -  Hieu Do T
AU  -  Svirskaite A
AU  -  van der Spek E
AU  -  Haukas E
AU  -  Knut-Bojanowska D
AU  -  Ypma PF
AU  -  Blimark CH
AU  -  Mellqvist UH
AU  -  van de Donk NWCJ
AU  -  Sonneveld P
AU  -  Klostergaard A
AU  -  Vangsted AJ
AU  -  Abildgaard N
AU  -  Zweegman S.
PY  - 2023
JO  - Hemasphere
DO  - 10.1097/hs9.0000000000000940
UR  - https://doi.org/10.1097/hs9.0000000000000940
ER  -

APA

K, G., FH, S., B, V. D. H., MD, L., MR, S., M, H., MBL, L., JC, R., A, W., D, S., P, A., T, H. D., A, S., E, V. D. S., E, H., D, K., PF, Y., CH, B., UH, M., NWCJ, V. D. D., P, S., A, K., AJ, V., N, A., & S., Z. (2023). Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.. Hemasphere. https://doi.org/10.1097/hs9.0000000000000940

Source records

europe-pmc · retrieved 2026-09-26T06:42:07.197Z
doaj · retrieved 2026-09-26T06:42:07.186Z